Background: Subacromialimpingement syndrome (SIS) is characterized by shoulder pain and restriction in range of motion (ROM), which lead to debility and decrease quality of life (QoL). Duloxetine could provide persistent long-term pain relief in chronic musculoskeletal pain. Therefore, we aimed to investigate the efficacy of duloxetine in stage I or II SIS patients through comparing the nonsteroidal anti-inflammatory drugs (NSAIDs) treatment.Methods: The patients diagnosed with stage I or II SISwere randomly assigned into the duloxetine group (N= 37) and NSAIDs group (N= 37). Duloxetine group patients started on oral duloxetine 40 mg per day for one week and then titrated up to 60 mg per day for one week. NSAIDs group patients received oral loxoprofen sodium tablets 60mg3 times a day for two weeks. The standard measures for investigating the efficacy include pain intensity (VAS), ROM, shoulder functional status, and the QoL at baseline, end of treatment, and at 1 and 3 months follow-up.Results: 74 eligible patients completed the treatment and evaluation. Both treatment groups improved significantly from baseline over time. And all parameters of pain intensity, shoulder functionalstatus and QoL in the duloxetine group were significantly better than those in the NSAIDs group.And no one manifested SIS recurrence and side effects during the entire follow-up period.Conclusions: Both duloxetine and NSAIDs can be beneficial in the rehabilitation of stage I or II SIS patients. Moreover, duloxetine resulted in improvements in outcomes greater than NSAIDs for the treatment of SIS. The current results indicated that duloxetine treatment might be used as a new safe and effective alternative for SIS. Given the encouraging results of this study, it would be worthwhile to confirm our findings in randomized placebo-controlled multicentre clinical trials.